Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Full results and management commentary in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- First NDA submitted for seralutinib in PAH, creating a major regulatory catalyst ahead of potential FDA filing acceptance and approval
- FDA acceptance could unlock up to approximately $125 million in additional committed capital, supporting potential 2027 commercialization
- Cash, equivalents and marketable securities fell to $51.2 million from $57.0 million quarter over quarter, highlighting near-term funding dependence
- Quarterly revenue rose to $38.4 million, primarily from accounting recognition tied to reacquiring worldwide seralutinib rights from Chiesi
- Net loss remained $48.1 million, while a $56.5 million warrant-liability remeasurement materially affected quarterly results、】【
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.